Supernus Pharmaceuticals (SUPN) Upgraded to Buy at Janney Montgomery Scott

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by equities research analysts at Janney Montgomery Scott from a “neutral” rating to a “buy” rating in a note issued to investors on Monday.

A number of other analysts have also commented on the company. ValuEngine lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. B. Riley reaffirmed a “buy” rating and issued a $50.00 price target on shares of Supernus Pharmaceuticals in a research note on Monday, November 20th. Zacks Investment Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Stifel Nicolaus raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research note on Tuesday, November 7th. Finally, SunTrust Banks reiterated a “buy” rating and issued a $61.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $49.60.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at $37.20 on Monday. Supernus Pharmaceuticals has a 52 week low of $20.70 and a 52 week high of $50.04. The company has a market capitalization of $1,906.95, a price-to-earnings ratio of 35.09, a P/E/G ratio of 1.57 and a beta of 1.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. The company’s revenue was up 41.5% compared to the same quarter last year. analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares in the company, valued at $623,250. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $47.60, for a total value of $2,380,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 150,000 shares of company stock valued at $7,055,350. 6.70% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of SUPN. BlackRock Inc. increased its holdings in shares of Supernus Pharmaceuticals by 0.5% during the second quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock valued at $289,962,000 after acquiring an additional 31,331 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Supernus Pharmaceuticals by 39.1% during the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after acquiring an additional 984,200 shares in the last quarter. State Street Corp increased its holdings in shares of Supernus Pharmaceuticals by 3.1% during the second quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock valued at $60,230,000 after acquiring an additional 42,165 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of Supernus Pharmaceuticals by 24.5% during the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock valued at $58,675,000 after acquiring an additional 267,971 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Supernus Pharmaceuticals by 10.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,268,082 shares of the specialty pharmaceutical company’s stock valued at $54,654,000 after acquiring an additional 122,042 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

WARNING: “Supernus Pharmaceuticals (SUPN) Upgraded to Buy at Janney Montgomery Scott” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/12/04/supernus-pharmaceuticals-supn-upgraded-to-buy-at-janney-montgomery-scott.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply